Product Description
Mechanisms of Action: Nucleoside Analogue, DNA Polymerase Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections|Chickenpox
Phase 2: Neuralgia, Postherpetic|Herpes Zoster
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00652184 |
Shingles | P2 |
Unknown status |
Herpes Zoster|Neuralgia, Postherpetic |
2009-06-01 |
2019-03-18 |
Treatments |
|
NCT00002358 |
255A | P3 |
Completed |
HIV Infections|Chickenpox |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/19/2024 |
PubMed |
Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD. |
|
01/01/2021 |
PubMed |
Identification of potential antivirals against SARS-CoV-2 using virtual screening method. |
|
08/01/2020 |
PubMed |
Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir. |
|
01/29/2019 |
News Article |
Certara Launches Version 18 of its Physiologically-based Pharmacokinetic (PBPK) Simcyp Simulator |